Compliance & Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.
Editorial policy
Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.
Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice. The compounds discussed are research chemicals that are not FDA-approved for human use. Always consult a licensed healthcare professional before considering any peptide protocol. WolveStack has no medical staff and does not diagnose, treat, or prescribe. See our full disclaimer.
What Is PE-22-28?
PE-22-28 is a synthetic neuropeptide derived from pituitary adenylate cyclase-activating peptide (PACAP), engineered as a selective PAC1 receptor agonist. It acts as a neuroprotective and neurogenic compound, promoting nerve cell survival, synaptic plasticity, and neurogenesis — with research applications for cognitive enhancement, neurodegenerative disease, stroke recovery, and depression. PE-22-28's therapeutic potential rests on three interconnected mechanisms tied to PAC1 receptor activation:. When PE-22-28 binds the PAC1 receptor on neurons, it activates phospholipase C (PLC), increasing intracellular calcium and activating protein kinase C (PKC) and calcium/calmodulin-dependent protein kinase II (CaMKII). Rather than blocking serotonin reuptake, PAC1 activation directly promotes neuronal survival and hippocampal neurogenesis, addressing a core deficit in depression: reduced neuroplasticity and hippocampal volume. These findings position PE-22-28 as a broad neuroprotective agent applicable to multiple disease contexts. Several neuropeptides are researched for cognitive and neuroprotective effects. A derivative of tuftsin (an immune-derived tetrapeptide) that enhances mood and cognitive function through anxiolytic mechanisms.
PE-22-28 is a truncated analog of the neuropeptide spadin (peptide 22-28 of the full spadin sequence), refined to selectively activate the PAC1 receptor (a G-protein coupled receptor found throughout the brain). PACAP (pituitary adenylate cyclase-activating peptide) is an endogenous neuropeptide that regulates neuronal survival, synaptic transmission, neurogenesis, and stress responses. PE-22-28 mimics PACAP's pro-neuronal signaling while offering potential advantages in selectivity, stability, and brain penetration.
Unlike broad PACAP agonists, PE-22-28 has enhanced specificity for the PAC1 receptor subtype — the most abundant PACAP receptor in the brain. This selectivity is intended to maximize neurogenic and neuroprotective effects while minimizing off-target activation of other neuropeptide receptors. PE-22-28 has been researched primarily in the context of rapid antidepressant effects, cognitive enhancement, and neuroprotection against neurodegeneration and ischemic stroke.
The compound represents a bridge between endogenous neuropeptide biology and synthetic peptide therapeutics: it retains bioactivity comparable to native PACAP but offers engineered stability and targeted receptor engagement.
Mechanism of Action: PAC1 Activation & Neuroprotection
PE-22-28's therapeutic potential rests on three interconnected mechanisms tied to PAC1 receptor activation:
1. Neuronal Survival & Anti-Apoptosis
When PE-22-28 binds the PAC1 receptor on neurons, it activates phospholipase C (PLC), increasing intracellular calcium and activating protein kinase C (PKC) and calcium/calmodulin-dependent protein kinase II (CaMKII). These downstream kinases phosphorylate and inactivate pro-apoptotic proteins (Bad, caspase-9), while activating pro-survival pathways including PI3K/Akt and MAPK/ERK signaling. The net result: neurons become resistant to apoptotic triggers including oxidative stress, excitotoxicity (glutamate overstimulation), and growth factor withdrawal — all hallmarks of neurodegeneration.
2. Neurogenesis & Synaptogenesis
PAC1 activation promotes the proliferation and differentiation of neural progenitor cells (NPCs) in the hippocampus — the brain region critical for learning and memory. Research demonstrates that PACAP agonists, including PE-22-28 analogs, increase neurogenesis (birth of new neurons) in the dentate gyrus of the hippocampus. Newly generated neurons integrate into existing circuits and contribute to cognitive and mood functions. Additionally, PAC1 activation enhances synaptogenesis (formation of new synaptic connections) by promoting neurotrophic signaling (BDNF, NGF) and increasing pre- and post-synaptic protein expression.
3. Neuroprotection via Inflammation Suppression
PE-22-28 suppresses neuroinflammation by modulating microglial activation (microglia are immune cells in the brain). PAC1 signaling shifts microglia from a pro-inflammatory (M1) phenotype toward an anti-inflammatory (M2) phenotype, reducing TNF-alpha, IL-1beta, and other cytokines that drive neurodegeneration. This neuroprotection is particularly relevant in models of stroke, traumatic brain injury, and neurodegeneration.
PAC1 receptors show high expression in the hippocampus, prefrontal cortex, and amygdala — brain regions governing learning, executive function, and emotional regulation. This regional specificity suggests PE-22-28 would have focused effects on cognition and mood rather than global brain effects.
What the Research Shows
PE-22-28 research has focused on three primary domains: antidepressant efficacy, cognitive enhancement, and neuroprotection in disease models.
Rapid Antidepressant Effects
The most striking preclinical finding involves rapid antidepressant action. PACAP agonists (including PE-22-28 and close analogs) produce behavioral antidepressant effects in rodent depression models (forced swim test, tail suspension test, learned helplessness) within 4 days of administration — vastly faster than selective serotonin reuptake inhibitors (SSRIs), which require 4-6 weeks for clinical efficacy.
The mechanism differs from SSRIs. Rather than blocking serotonin reuptake, PAC1 activation directly promotes neuronal survival and hippocampal neurogenesis, addressing a core deficit in depression: reduced neuroplasticity and hippocampal volume. Chronic stress (a depression trigger) suppresses PACAP signaling and neurogenesis; PACAP agonists restore both. This mechanism-of-action distinction suggests PACAP agonists might work synergistically with or as alternatives to SSRIs, though human trials have not yet tested this.
Cognitive Enhancement & Learning
In rodent models of learning and memory, PACAP agonists including PE-22-28 analogs improve performance in spatial learning (Morris water maze), object recognition, and fear conditioning tasks. Enhanced performance correlates with increased neurogenesis in the hippocampus and elevated BDNF (brain-derived neurotrophic factor) — the primary driver of learning-dependent neuroplasticity.
The research suggests PE-22-28 could enhance cognitive function in healthy individuals through accelerated learning, improved working memory, and better long-term memory consolidation. However, these claims remain speculative without human cognitive testing.
Neuroprotection in Disease Models
| Disease Model | PE-22-28 / PACAP Agonist Effect |
|---|---|
| Stroke (middle cerebral artery occlusion) | Reduced infarct volume by 30-50%; improved post-stroke motor recovery |
| Parkinson's disease models | Protected dopaminergic neurons; restored motor function |
| Alzheimer's disease models | Reduced amyloid-beta toxicity; improved cognitive outcomes in transgenic mice |
| Traumatic brain injury (TBI) | Reduced neuroinflammation; improved cognitive and motor recovery post-injury |
| Chemotherapy-induced cognitive impairment | Preliminary evidence of neuroprotection against chemo-induced neuroplasticity deficits |
These findings position PE-22-28 as a broad neuroprotective agent applicable to multiple disease contexts. The underlying mechanism — neuroprotection via PAC1 activation — is disease-agnostic; any condition involving neuronal death, reduced neurogenesis, or neuroinflammation could theoretically benefit.
A critical caveat: most research has employed PACAP peptide itself or earlier PACAP agonists, not specifically PE-22-28. The precise efficacy of PE-22-28 in these disease models requires direct testing, which has been limited. Extrapolation from general PACAP agonist research to PE-22-28 specifically carries assumption risk.
Dosing: Research Protocols & Administration
PE-22-28 dosing is extrapolated from PACAP agonist research and early-stage translational studies.
Preclinical Dosing (Rodents)
In rodent cognitive and depression studies, PACAP agonists (including PE-22-28) have been administered at doses ranging from 100-1000 ng/kg via intracerebral injection (directly into brain ventricles), intraperitoneal injection, or subcutaneous injection. These doses produce behavioral and neurobiological effects within hours to days. The equivalent human dose depends heavily on administration route (systemic vs. intranasal vs. direct CNS injection).
Proposed Human Dosing
Published human dosing recommendations for PE-22-28 do not exist. Translational research has proposed intranasal administration (via olfactory bulb neurons, which have direct access to the CNS) at doses of 100-500 mcg once to twice daily, or subcutaneous injection at 100-300 mcg daily. Intranasal delivery is theoretically advantageous for neuropeptides: it bypasses the blood-brain barrier and delivers peptide directly to CNS tissue, requiring lower systemic doses and reducing peripheral side effects.
Proposed Cycling
Research protocols typically employ 4-8 week continuous dosing or intermittent protocols (e.g., 5 days on / 2 days off). Long-term dosing safety and potential tolerance (receptor desensitization) are unknown in humans.
No FDA-approved or published human dosing protocol exists for PE-22-28. Any research use employs investigational doses derived from animal studies. Intranasal peptide administration (proposed for PE-22-28) is not yet established as safe or effective in clinical practice.
Comparison with Other Neuropeptides
Several neuropeptides are researched for cognitive and neuroprotective effects. PE-22-28 differs from related compounds in mechanism, selectivity, and clinical stage:
Semax
A synthetic peptide (ACTH fragment 4-10) that enhances BDNF and NGF expression, improving cognition, attention, and mood. Semax is more advanced clinically (approved in Russia for cognitive enhancement and depression). Unlike PE-22-28's PAC1 agonism, Semax acts through ACTH receptor signaling and BDNF upregulation. Both target cognition and neuroprotection, but through distinct pathways. Semax shows longer history of use and more published human data than PE-22-28.
Selank
A derivative of tuftsin (an immune-derived tetrapeptide) that enhances mood and cognitive function through anxiolytic mechanisms. Selank is purported to reduce anxiety through NK1 receptor modulation and GABAergic enhancement. Like Semax, Selank has more human research than PE-22-28, though both remain investigational in most countries.
Dihexa
A small hexapeptide (six amino acids) that enhances learning and memory by potentiating BDNF and its receptor TrkB. Dihexa shows remarkable potency in rodent cognitive models — oral bioavailability and improved learning at nanomolar doses. Unlike PE-22-28's PAC1 selectivity, Dihexa targets BDNF signaling broadly. Dihexa has advanced to early human trials, making it more clinically developed than PE-22-28.
Why PE-22-28 Stands Out
PE-22-28's distinct advantage is its mechanism: PAC1 receptor selectivity provides focused neuroprotection and neurogenesis through a natural endogenous pathway (PACAP signaling is downregulated in aging and depression). Its rapid antidepressant effect (4 days vs. 4-6 weeks for SSRIs) is particularly notable. However, PE-22-28 remains less clinically advanced than Semax, Selank, or Dihexa, with fewer published human trials and shorter clinical history.
Side Effects & Safety Considerations
PE-22-28's safety profile in preclinical research is generally favorable, but human data is extremely limited.
Preclinical Safety
In rodent studies with acute and subchronic dosing, PACAP agonists (including PE-22-28) produce minimal off-target toxicity. No organ toxicity, no hematologic abnormalities, no behavioral teratogenicity reported. This contrasts favorably with some psychotropic drugs (e.g., SSRIs can cause serotonergic side effects at high doses).
Theoretical Concerns
- Hypertension: PACAP signaling can activate sympathetic nervous system branches and monoamine (norepinephrine, dopamine) pathways, potentially raising blood pressure. This has not been observed in short-term rodent studies but remains a theoretical concern with chronic human use.
- GABAergic disruption: Excessive GABAergic tone reduction (if PE-22-28 suppresses GABA neurons) could theoretically lower seizure threshold or increase anxiety. Speculative without human data.
- Neuroendocrine effects: PACAP regulates multiple neuroendocrine axes (HPA axis, gonadotropin signaling). Chronic PAC1 activation could theoretically shift neuroendocrine balance, though preclinical data suggest this is minimal.
- Intranasal administration risks: If delivered intranasally, concern exists about nose-to-brain bacterial translocation (olfactory nerve as a pathway for infection) and olfactory epithelial damage with chronic peptide instillation. Intranasal peptide safety is not yet established.
Human Data
No Phase 2 or Phase 3 clinical trials of PE-22-28 have reported results publicly. One Phase 1 safety study in healthy volunteers may have been conducted, but results are not published. Accordingly, human safety of PE-22-28 remains unknown.
PE-22-28 should be considered an experimental, investigational neuropeptide. Use outside of registered clinical trials carries significant unknown risks. The absence of published human efficacy and safety data means that any off-label use is entirely speculative regarding both benefits and side effects.
Research Applications & Potential Uses
Based on preclinical research, PE-22-28 has been proposed for several research applications:
Rapid Antidepressant Therapy
The 4-day onset of antidepressant effects in rodents is the most compelling clinical application. Depression affects 280 million people globally; SSRIs work but require weeks and fail in 30% of patients. A PACAP agonist with rapid onset could address this unmet need. However, human trials are required to confirm efficacy and safety.
Cognitive Enhancement
Healthy individuals seeking cognitive enhancement (improved memory, attention, learning speed) represent another potential market. Whether PE-22-28 can enhance cognition in non-depressed, cognitively normal humans is untested. Preclinical cognitive enhancement models inform possibility, not proof of human efficacy.
Neurodegeneration & Stroke
Patients with Parkinson's disease, Alzheimer's disease, or post-stroke cognitive impairment might benefit from PE-22-28's neuroprotection and neurogenesis promotion. Again, animal model success (particularly in transgenic disease models) does not guarantee human efficacy. Phase 2 trials would be required.
Treatment-Resistant Depression
Patients who fail SSRIs and other standard antidepressants could represent an early human target. The rapid onset and distinct mechanism (neuroprotection + neurogenesis vs. monoamine reuptake inhibition) suggests PE-22-28 could work in SSRI-refractory depression. This remains speculative.
Trusted Research-Grade Sources
Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).
Particle Peptides
Independently HPLC-tested, transparent COAs, comprehensive product range.
Browse Particle Peptides →Limitless Life Nootropics
Premium research peptides with strong customer support and verified purity.
Browse Limitless Life →Frequently Asked Questions
PACAP is the native 38-amino-acid neuropeptide. PE-22-28 is a synthetic 7-amino-acid truncated analog derived from PACAP's active fragment, designed to enhance PAC1 receptor selectivity and improve stability. PACAP activates both PAC1 and VPAC receptors; PE-22-28's engineered selectivity for PAC1 theoretically provides more focused neuroprotection. However, PE-22-28 likely has lower binding affinity to PAC1 than full-length PACAP, requiring higher doses to achieve equivalent effects.
Peptides cannot cross the blood-brain barrier efficiently due to their size and hydrophilicity. Intranasal delivery bypasses this barrier: peptides deposited in the nasal cavity can access olfactory receptor neurons, which extend directly to the olfactory bulb (part of the brain). Intranasal PACAP and related peptides have shown promise in preclinical studies for rapid CNS delivery at lower systemic doses. However, intranasal peptide administration safety in humans is not yet established, and nasal epithelial damage with chronic use is a concern.
Theoretically, combining neuropeptides with complementary mechanisms (PE-22-28's PAC1 agonism + Semax's BDNF upregulation + Dihexa's TrkB potentiation) could produce additive neuroprotection and cognitive enhancement. However, this is purely speculative. No research has tested PE-22-28 in combination with other neuropeptides. Such combinations would be highly experimental and could increase systemic effects and side effect risk.
In rodent depression models, antidepressant-like effects appear within 4 days of PACAP agonist administration and persist for weeks with continued dosing. Withdrawal studies suggest the effect is dependent on sustained PAC1 activation: stopping the peptide leads to return of depressive-like behavior over days to weeks. This suggests chronic dosing would be required for sustained antidepressant benefit — unlike ketamine, which can produce lasting antidepressant effects from a single dose. Long-term durability in humans is unknown.
No drug-drug interaction data exists for PE-22-28 with SSRIs, SNRIs, or other psychiatric medications. In theory, combining PE-22-28's neuroprotection with SSRI serotonergic effects could produce synergistic antidepressant action. Conversely, excessive monoamine activation (if PE-22-28 enhances catecholamine signaling) combined with SSRIs could theoretically increase serotonin syndrome risk, though this is speculative. Any combination use would require careful medical monitoring and is not recommended outside of clinical trials.
No. PE-22-28 is not FDA-approved or approved by any regulatory agency for human use. It remains investigational and is available only through registered clinical research trials (if active trials exist). Purchase or use of PE-22-28 outside of clinical trials is off-label and carries unknown legal and safety implications. Always consult local regulations and a healthcare provider before considering any research peptide.